New York, NY – July 21, 2014
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, today announced that it has secured cGMP manufacturing of ANAVEX 2-73 for its drug candidate trial supplies.
“We are delighted to have the active drug product (API) manufactured and available for our Phase 2a trial,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “We look forward to initiating clinical trials with ANAVEX PLUS for the treatment of Alzheimer’s disease, which remains on track to commence in 2014 with data from the first part of the trial expected to be reported in mid 2015.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp.(www.anavex.com) is a clinical-stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer’s disease, other CNS diseases and various types of cancer. ANAVEX 2-73, an orally available drug candidate developed to treat Alzheimer’s disease through potential disease modification, has undergone an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg. Results from preclinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties. A highly encouraging synergistic effect has also been observed between ANAVEX 2-73 and donepezil (Aricept®). The combined therapeutic, called ANAVEX PLUS, produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually. Anavex is a publicly traded corporation quoted as AVXL.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information Anavex Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: firstname.lastname@example.org